Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus

Author(s): Michael W. Ferenczy

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 19 , 2007

Become EABM
Become Reviewer


Herpes Simplex Virus Type 1 (HSV-1) infection is widespread and causes significant disease. A number of prophylactic vaccine strategies have elicited protective immunity in animal models, but no human vaccine has yet been effective. Asymptomatic HSV-1 infection is common, demonstrating that the immune system is able to control infection, despite failure to clear the virus. Therefore, therapeutic vaccination may be a viable strategy against HSV-1. This review will discuss the epidemiology, molecular biology, and immune response to HSV-1, prophylactic and therapeutic vaccine strategies, and the potential of future therapeutic HSV-1 vaccines to reduce or eliminate HSV-1 pathology.

Keywords: HSV-1, therapeutic vaccine, cytokine adjuvant, DNA vaccine

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [1975 - 1988]
Pages: 14
DOI: 10.2174/138161207781039779
Price: $65

Article Metrics

PDF: 3